Novogene Europe Team with NovaSeq X Plus
MUNICH, July 3, 2025 — Novogene Europe has announced the installation of its fifth Illumina NovaSeq X Plus sequencing system, significantly enhancing its high-throughput sequencing capabilities to meet the surging demand across Europe. This strategic move not only reinforces Novogene’s status as a leading genomics partner in the region but also promises unprecedented speed, data quality, and scalability for large-scale research projects.
“Investing in the NovaSeq X Plus allows us to meet the increasing needs of our clients with unmatched speed and precision,” said Tingting Zhou, Vice President at Novogene Europe. “This expansion ensures we remain at the forefront of sequencing innovation, empowering researchers with unmatched speed and data quality to drive scientific breakthroughs.”
Advanced Sequencing Capabilities
The NovaSeq X Plus, Illumina’s most advanced sequencing platform, is capable of generating up to 16 terabases of data in just 48 hours. This capability is crucial for applications such as whole-genome sequencing, single-cell RNA analysis, and complex population studies. As researchers worldwide grapple with increasingly complex genomic questions, the need for both scale and precision has never been more critical.
The integration of an additional NovaSeq X Plus at Novogene Europe ensures that customers can tackle ambitious projects with confidence. The cutting-edge technology promises faster results without compromising on data integrity or environmental responsibility.
Strengthening Partnerships and Innovation
Bas Verhoef, Senior Vice President and Head of Region, Europe at Illumina, commented on the enduring partnership between the two companies: “For more than a decade, Illumina and Novogene have fostered an enduring relationship as together, we broaden the scope of genomics. The NovaSeq X Plus is Illumina’s most rapidly adopted and utilized high-throughput sequencing platform to date, ensuring that researchers have access to the latest technology that provides reliable, swift, and cost-effective next-generation sequencing services.”
“Customers are already raving about the powerful capabilities of our recent software upgrade,” Verhoef added.
Expanding Technological Horizons
In recent years, Novogene Europe has systematically integrated state-of-the-art technologies across its service portfolio, including genomic, transcriptomic, microbial, and single-cell sequencing. The localized deployment in European laboratories allows for tailored support while maintaining global standards of excellence.
Novogene’s commitment to innovation and excellence is evident in its continued expansion and adoption of cutting-edge technologies. The company’s vision is to remain a global leader in genomics services and solutions, leveraging its vast sequencing capacity and deep scientific expertise to help clients achieve their research goals.
The Future of Genomics
As the field of genomics continues to evolve, the demand for high-throughput sequencing solutions is expected to grow. Novogene’s strategic investment in the NovaSeq X Plus positions the company to meet these demands head-on, providing researchers with the tools they need to push the boundaries of scientific discovery.
Looking ahead, Novogene Europe is poised to play a pivotal role in the advancement of genomic research, offering unparalleled support and innovation to its clients. With its robust infrastructure and commitment to excellence, the company is well-prepared to tackle the challenges and opportunities that lie ahead in the rapidly evolving world of genomics.
For more information, contact Novogene Europe at [email protected].
